Business · 13/01/2010

FDA Releases Draft Guidance for IRB Continuing Review After Clinical Investigation Approval

The Food and Drug Administration (FDA) has released a draft guidance document to help institutional review boards (IRBs) and other stakeholders understand their responsibilities in conducting continuing reviews of clinical investigations after initial approval. The guidance aims to ensure the protection of human subjects in clinical trials.